Novo Nordisk recently sent a letter warning certain 340B providers that failure to submit claims data could result in the loss of 340B pricing.

Novo Nordisk Threatens to End 340B Pricing Over In-House Claims Data Policy

June 30, 2026 William Newton, Editor-in-Chief 340B Report Views

Novo Nordisk recently warned certain 340B covered entities that they could lose access to 340B pricing if they do not [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!